- Home
- VERA
as 05-30-2025 4:00pm EST
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 1.6B | IPO Year: | 2021 |
| Target Price: | $64.00 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $18.53 - $51.61 | Next Earning Date: | 05-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Vera Therapeutics Inc. News
VERA Breaking Stock News: Dive into VERA Ticker-Specific Updates for Smart Investing
GlobeNewswire
23 days ago
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
a month ago
Vera Therapeutics' Q1 Net Loss Widens
GlobeNewswire
a month ago
Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
GlobeNewswire
2 months ago
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Benzinga
2 months ago
Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch
GlobeNewswire
2 months ago
Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN
GlobeNewswire
3 months ago
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
3 months ago
Wedbush Adjusts Price Target on Vera Therapeutics to $34 From $38, Maintains Neutral Rating
Compare VERA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VERA Vera Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.